000302890 001__ 302890
000302890 005__ 20250718114121.0
000302890 0247_ $$2doi$$a10.1016/j.euo.2025.06.007
000302890 0247_ $$2pmid$$apmid:40640052
000302890 037__ $$aDKFZ-2025-01430
000302890 041__ $$aEnglish
000302890 082__ $$a610
000302890 1001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b0$$eFirst author
000302890 245__ $$aDo We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial.
000302890 260__ $$aAmsterdam$$bElsevier$$c2025
000302890 3367_ $$2DRIVER$$aarticle
000302890 3367_ $$2DataCite$$aOutput Types/Journal article
000302890 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1752752342_14021
000302890 3367_ $$2BibTeX$$aARTICLE
000302890 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302890 3367_ $$00$$2EndNote$$aJournal Article
000302890 500__ $$a#EA:C130#LA:C130# / epub
000302890 520__ $$aIn general, low-risk and favorable intermediate-risk prostate cancers (PCs; International Society of Urological Pathology grade group [GG] 1 and GG 2) are slow-growing cancers with low metastatic potential. Active surveillance is recommended for GG 1 PC and can be recommended for GG 2 PC in the absence of adverse pathological parameters. Therefore, the question arises as to when low-grade PC should be detected in a screening setting. We conducted an analysis of the group with intermediate prostate-specific antigen (PSA) risk (1.5-2.99 ng/ml) from the PROBASE screening trial for young men (starting age 45 yr) and evaluated 159 biopsies performed for confirmed PSA ≥3 ng/ml in the first two biennial screening rounds. Of these biopsies, 37% were positive, with 78% (46/59) showing GG 1 or GG 2 disease. Only 0.8% of men with intermediate risk (13 of 1661 men screened) had GG 3-5 PC and would have experienced a delay in diagnosis of between 1 and 3 yr if screening were performed at 5-yr intervals. These results suggest that the screening interval could be extended from 2 yr to 5 yr for men aged 45 yr at intermediate risk, similar to the interval for men at low risk (PSA <1.5 ng/ml). This would reduce unnecessary testing and overdiagnosis in nearly 10% of the screening population aged 45 yr.
000302890 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000302890 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302890 650_7 $$2Other$$aGrade group
000302890 650_7 $$2Other$$aIntermediate risk
000302890 650_7 $$2Other$$aInternational Society of Urological Pathology
000302890 650_7 $$2Other$$aProstate cancer
000302890 650_7 $$2Other$$aScreening
000302890 7001_ $$0P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aKrilaviciute, Agne$$b1
000302890 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b2
000302890 7001_ $$0P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4$$ade Vrieze, Maxime$$b3
000302890 7001_ $$aLakes, Jale$$b4
000302890 7001_ $$aKuczyk, Markus A$$b5
000302890 7001_ $$aHarke, Nina N$$b6
000302890 7001_ $$aDebus, Jürgen$$b7
000302890 7001_ $$aGrott, Christoph A$$b8
000302890 7001_ $$aGschwend, Jürgen E$$b9
000302890 7001_ $$aHerkommer, Kathleen$$b10
000302890 7001_ $$aSoehne, Victoria A$$b11
000302890 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b12
000302890 7001_ $$aKristiansen, Glen$$b13
000302890 7001_ $$aHadaschik, Boris$$b14
000302890 7001_ $$aArsov, Christian$$b15
000302890 7001_ $$aAntoch, Gerald$$b16
000302890 7001_ $$aSchimmöller, Lars$$b17
000302890 7001_ $$aGiesel, Frederik L$$b18
000302890 7001_ $$aMakowski, Marcus R$$b19
000302890 7001_ $$aWacker, Frank$$b20
000302890 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b21
000302890 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b22
000302890 7001_ $$0P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aBecker, Nikolaus$$b23$$eLast author
000302890 773__ $$0PERI:(DE-600)2945338-0$$a10.1016/j.euo.2025.06.007$$gp. S2588931125001865$$pnn$$tEuropean urology oncology$$vnn$$x2588-9311$$y2025
000302890 909CO $$ooai:inrepo02.dkfz.de:302890$$pVDB
000302890 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000302890 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000302890 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000302890 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000302890 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000302890 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000302890 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000302890 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000302890 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000302890 9141_ $$y2025
000302890 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL ONCOL : 2022$$d2024-12-16
000302890 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000302890 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000302890 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000302890 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000302890 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000302890 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000302890 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000302890 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR UROL ONCOL : 2022$$d2024-12-16
000302890 9202_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000302890 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000302890 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000302890 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x2
000302890 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x3
000302890 9200_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000302890 980__ $$ajournal
000302890 980__ $$aVDB
000302890 980__ $$aI:(DE-He78)C130-20160331
000302890 980__ $$aI:(DE-He78)C060-20160331
000302890 980__ $$aI:(DE-He78)E010-20160331
000302890 980__ $$aI:(DE-He78)C020-20160331
000302890 980__ $$aUNRESTRICTED